title: The efficacy of nonestrogenic therapy to hot flashes in cancer patients under hormone manipulation therapy: a systematic review and meta-analysis.
abstract: OBJECTIVE
  The incidence of hot flashes under hormone manipulation therapy is so high that this symptom caused by sex hormone blocking agents has been bothering patients and has a negative impact on their quality of life. Venlafaxine and gabapentin are most promising novel nonestrogenic agents to control the symptom. We seek to quatitatively summarize the efficacy of these novel agents.
  
  
  METHODS
  We conducted a meta-analysis of randomized controlled studies on the efficacy of venlafaxine/gabapentin to hot flashes in cancer patient under hormone deprivation therapies. A search for Medline, Embase, Cochrane Central Register of Controlled Trials, Ichushi, and Google Scholar yielded 733 citations, which were independently assessed by two authors. We estimated overall effect sizes and its 95 % confidence intervals (CI) for the efficacy of these agents compared with the controls with standardized mean difference.
  
  
  RESULTS
  A total of 5 studies involving 588 cancer patients with hot flashes finally fulfilled the predefined inclusion criteria. Overall effect size of the efficacy of venlafaxine/gabapentin was -0.630 (95 % CI [-0.801, -0.459]).
  
  
  CONCLUSIONS
  Venlafaxine/gabapentin significantly improved hot flashes in cancer patients under hormone manipulation therapies.
authors: Division of Hematology/Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA, 02215, USA, nyamaguchi@chpnet.org.
authors: N
authors: N
authors: Yamaguchi
authors: Y
authors: Y
authors: Okajima
authors: T
authors: T
authors: Fujii
authors: A
authors: A
authors: Natori
authors: D
authors: D
authors: Kobayashi
mesh_terms: D000588:Amines / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D003509:Cyclohexanecarboxylic Acids / Q000627:therapeutic use*; D003511:Cyclohexanols / Q000627:therapeutic use*; D000077206:Gabapentin; D019584:Hot Flashes / Q000139:chemically induced / Q000188:drug therapy*; D006801:Humans; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D000069470:Venlafaxine Hydrochloride; D005680:gamma-Aminobutyric Acid / Q000627:therapeutic use*
chemical_list: D000588:Amines; D018931:Antineoplastic Agents, Hormonal; D003509:Cyclohexanecarboxylic Acids; D003511:Cyclohexanols; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D000069470:Venlafaxine Hydrochloride
references: J Sex Med. 2008 Sep;5(9):2202-8
references: 18638000
references: CMAJ. 2007 Apr 10;176(8):1091-6
references: 17420491
references: J Clin Epidemiol. 2006 Jan;59(1):7-10
references: 16360555
references: Cancer. 1998 May 1;82(9):1682-91
references: 9576289
references: J Clin Oncol. 1995 Nov;13(11):2737-44
references: 7595732
references: J Clin Oncol. 2011 Oct 10;29(29):3862-8
references: 21911720
references: Cochrane Database Syst Rev. 2010 Sep 08;(9):CD004923
references: 20824841
references: BMJ. 2003 Sep 6;327(7414):557-60
references: 12958120
references: Lancet. 2000 Dec 16;356(9247):2059-63
references: 11145492
references: Maturitas. 2005 Sep 16;52(1):78-85
references: 16143229
references: PLoS Med. 2009 Jul 21;6(7):e1000097
references: 19621072
references: J Clin Oncol. 2001 Dec 1;19(23):4280-90
references: 11731510
references: J Clin Oncol. 2010 Dec 10;28(35):5147-52
references: 21060031
references: Ann Oncol. 2009 Mar;20(3):542-9
references: 19129205
references: Lancet Oncol. 2010 Feb;11(2):147-54
references: 19963436
references: Br J Cancer. 2008 Dec 2;99(11):1763-8
references: 18985046
references: Urology. 1989 Mar;33(3):175-8
references: 2465644
references: Breast Cancer Res Treat. 2011 Apr;126(2):529-37
references: 20803066
references: Lancet. 2005 Sep 3-9;366(9488):818-24
references: 16139656
references: J Pain Symptom Manage. 2009 Apr;37(4):687-97
references: 18973980
references: Ann Oncol. 2007 Apr;18(4):689-93
references: 17229772
references: Breast Cancer Res Treat. 2009 Jun;115(3):573-80
references: 18670875
references: Climacteric. 2009 Aug;12(4):310-8
references: 19415540
references: BMJ. 2004 Jun 19;328(7454):1490
references: 15205295
references: J Clin Oncol. 2010 Feb 1;28(4):634-40
references: 20038728
references: N Engl J Med. 2009 Feb 5;360(6):573-87
references: 19196674
references: Oncologist. 2007 Jan;12(1):124-35
references: 17227907